Emerging Agents in the Treatment of Anthracycline- and Taxane-Refractory Metastatic Breast Cancer

Seminars in Oncology

Volumn 35, Issue SUPPL. 2, 2008, Pages

  Dean Colomb, Windy ^a   Esteva, Francisco J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DENILEUKIN DIFTITOX; DOCETAXEL; EPIRUBICIN; EPOTHILONE B; EPOTHILONE D; EXATECAN; FLUOROURACIL; GEMCITABINE; HALICHONDRIN B; IRINOTECAN; IXABEPILONE; LAPATINIB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; TANESPIMYCIN; TRABECTEDIN; TRASTUZUMAB; VINFLUNINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG STRUCTURE; DRUG TARGETING; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HUMAN; LONG TERM CARE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; SINGLE DRUG DOSE; STOMATITIS; TREATMENT DURATION; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DIOXOLES; DIPHTHERIA TOXIN; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; EPOTHILONES; FEMALE; FURANS; GLUTAMATES; GUANINE; HUMANS; INTERLEUKIN-2; KETONES; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; RECOMBINANT FUSION PROTEINS; TETRAHYDROISOQUINOLINES; VINBLASTINE;

EID: 41849101378     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.02.008     Document Type: Article

References (49)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Giordano S.H., Buzdar A.U., Smith T.L., et al. Is breast cancer survival improving?. Cancer 100 (2004) 44-52
3. Blum J.L., Jones S.E., Buzdar A.U., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17 (1999) 485-493
4. Fumoleau P., Largillier R., Clippe C., et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40 (2004) 536-542
5. Ahn J.H., Kim S.B., Kim T.W., et al. Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 19 (2004) 547-553
6. Donadio M., Ardine M., Berruti A., et al. Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes. Oncology 69 (2005) 408-413
7. Lin P.C., Wang W.S., Yang M.H., et al. Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer. J Chin Med Assoc 69 (2006) 304-309
8. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
9. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
10. Dent S., Messersmith H., and Trudeau M. Gemcitabine in the management of metastatic breast cancer: A systematic review. Breast Cancer Res Treat (2007) [Epub ahead of print]
11. Modi S., Currie V.E., Seidman A.D., et al. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer 6 (2005) 55-60
12. Rha S.Y., Moon Y.H., Jeung H.C., et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 90 (2005) 215-221
13. Smorenburg C.H., Bontenbal M., Seynaeve C., et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66 (2001) 83-87
14. Sánchez-Escribano Morcuende R., Alés-Martínez J.E., and Aramburo González P.M. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens. Clin Transl Oncol 9 (2007) 459-464
15. Frasci G., D'Aiuto G., Comella P., et al. A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients. Oncology 62 (2002) 25-32
16. Martin M., Ruiz A., Muñoz M., et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8 (2007) 219-225
17. Zelek L., Barthier S., Riofrio M., et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92 (2001) 2267-2272
18. Ray-Coquard I., Biron P., Bachelot T., et al. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer 82 (1998) 134-140
19. Vassilomanolakis M., Koumakis G., Demiri M., et al. Vinorelbine and cisplatin for metastatic breast cancer: A salvage regimen in patients progressing after docetaxel and anthracycline treatment. Cancer Invest 21 (2003) 497-504
20. Carrick S., Ghersi D., Wilcken N., et al. Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (2004) CD003374
21. Pegram M.D., and Slamon D.J. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 26 suppl 12 (1999) 89-95
22. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24 (2006) 2786-2792
23. Pectasides D., Pectasides M., Farmakis D., et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: A phase II study. Ann Oncol 14 (2003) 537-542
24. Zelek L., Cottu P., Tubiana-Hulin M., et al. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 20 (2002) 2551-2558
25. Petit T., Benider A., Yovine A., et al. Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. Anticancer Drugs 17 (2006) 337-343
26. Delozier T., Guastalla J.P., Yovine A., et al. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anticancer Drugs 17 (2006) 1067-1073
27. Perez E.A., Hillman D.W., Mailliard J.A., et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22 (2004) 2849-2855
28. Frasci G., D'Aiuto G., Thomas R., et al. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in anthracycline-paclitaxel-refractory breast cancer patients. Oncology 68 (2005) 391-397
29. O'Connor T., Rustum Y., Levine E., et al. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. Cancer Chemother Pharmacol 61 (2008) 125-131
30. Esteva F.J., Rivera E., Cristofanilli M., et al. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer 98 (2003) 900-907
31. Lee F.Y., Borzilleri R., Fairchild C.R., et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7 (2001) 1429-1437
32. Low J.A., Wedam S.B., Lee J.J., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23 (2005) 2726-2734
33. Denduluri N., Lee J.J., Walshe J., et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 25 (2007) 63-67
34. Thomas E., Tabernero J., Fornier M., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25 (2007) 3399-3406
35. Roché H., Yelle L., Cognetti F., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25 (2007) 3415-3420
36. Perez E.A., Lerzo G., Pivot X., et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25 (2007) 3407-3414
37. Spielmann M., Martin M., Namer M., et al. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: An interim analysis. Clin Breast Cancer 2 (2001) 47-51
38. O'Shaughnessy J.A., Clark R.S., Blum J.L., et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 6 (2005) 143-149
39. Kruczynski A., Colpaert F., Tarayre J.P., et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother Pharmacol 41 (1998) 437-447
40. Lobert S., Ingram J.W., Hill B.T., et al. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 53 (1998) 908-915
41. Bennouna J., Fumoleau P., Armand J.P., et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 14 (2003) 630-637
42. Campone M., Cortes-Funes H., Vorobiof D., et al. Vinflunine: A new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 95 (2006) 1161-1166
43. Dabydeen D.A., Burnett J.C., Bai R., et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 70 (2006) 1866-1875
44. Jordan M.A., Kamath K., Manna T., et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4 (2005) 1086-1095
45. Zelek L., Yovine A., Brain E., et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 94 (2006) 1610-1614
46. Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 33 suppl 3 (2006) S11-S16
47. Turturro F. Denileukin diftitox: A biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther 7 (2007) 11-17
48. Solit D.B., Basso A.D., Olshen A.B., et al. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63 (2003) 2139-2144
49. Zsebik B., Citri A., Isola J., et al. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett 104 (2006) 146-155